Equities

Immuno-Biological Laboratories Co Ltd

4570:TYO

Immuno-Biological Laboratories Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)445.00
  • Today's Change-14.00 / -3.05%
  • Shares traded150.60k
  • 1 Year change-25.46%
  • Beta0.8867
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments734614508
Total Receivables, Net190216174
Total Inventory322318327
Prepaid expenses------
Other current assets, total1617121
Total current assets1,2621,1651,130
Property, plant & equipment, net136119120
Goodwill, net------
Intangibles, net2.29----
Long term investments9595400
Note receivable - long term------
Other long term assets555556
Total assets1,6191,4341,705
LIABILITIES
Accounts payable4.355.703.93
Accrued expenses312517
Notes payable/short-term debt135130125
Current portion long-term debt/capital leases165.894.01
Other current liabilities, total718578
Total current liabilities258252228
Total long term debt8599105
Total debt236235234
Deferred income tax------
Minority interest------
Other liabilities, total114.623.92
Total liabilities353356337
SHAREHOLDERS EQUITY
Common stock503,0293,029
Additional paid-in capital1,0402,0612,061
Retained earnings (accumulated deficit)177(4010)(3720)
Treasury stock - common(1.99)(1.99)(1.99)
Unrealized gain (loss)------
Other equity, total------
Total equity1,2651,0791,368
Total liabilities & shareholders' equity1,6191,4341,705
Total common shares outstanding9.319.319.31
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.